Printer Friendly

Rexahn Pharmaceuticals begins treatment under Phase IIa trial of Supinoxin in metastatic TNBC negative breast cancer patients.

M2 EQUITYBITES-February 24, 2017-Rexahn Pharmaceuticals begins treatment under Phase IIa trial of Supinoxin in metastatic TNBC negative breast cancer patients

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company Rexahn Pharmaceuticals Inc (NYSE MKT:RNN) reported on Thursday the start of dosing of the patient under the Phase IIa clinical study of Supinoxin to evaluate the safety and efficacy of Supinoxin in patients with metastatic TNBC negative breast cancer (TNBC) who have failed prior treatments.

This Phase IIa clinical proof-of-concept study is an open-label evaluation of the safety and efficacy of the company's Supinoxin monotherapy in patients with metastatic triple negative breast cancer who have failed multiple prior chemotherapeutic regimens. The primary endpoint is progression free survival.

As part of the study, the company will recruit an initial ten patients, who will be enrolled at seven study sites in the US. The study can also be extended up to 50 patients, if warranted, based on the data readout from the initial cohort of patients.

The company added that Supinoxin (RX-5902) is an orally administered, potential first-in-class, small molecule modulator of the ?-catenin pathway - a key biological pathway that is activated in tumor cells leading to production of multiple cancer oncogenes and tumor proliferation and metastasis. Supinoxin modulates the pathway through inhibition of the interaction of phosphorylated p68 (a regulatory protein) with ?-catenin.

Triple negative breast cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) or Her2/neu. It is also more aggressive than other types of breast cancer and is more likely to recur.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Clinical report
Date:Feb 24, 2017
Words:277
Previous Article:Infinity Property And Casualty announces dividend of USD0.58 per share for quarter.
Next Article:Old Republic's board approves of special dividend of USD0.19 per share for quarter.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters